Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Jared Holz thought about taking one of the new GLP-1 drugs for weight loss for months before he actually filled the ...

We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...

Amycretin mimics the actions of glucagon-like peptide-1 (GLP-1) and amylin, hormones that play a role in reducing blood sugar ...

Amycretin, an oral weight loss drug, led to up to 13% body weight reduction in three months, showing potential for continued ...

However, after its phase 1 success with TERN-601, it will raise more money by taking advantage of its soaring stock price and ...

A new weight loss pill called amycretin has helped people lose up to 13% of their body weight in just three months, according ...

Another contender has emerged in the race to develop oral GLP-1 drugs for weight loss. Biolexis Therapeutics’ small molecule ...

People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the ...

The compound was oral amycretin -- an amylin and GLP-1 receptor co-agonist -- said Agnes Gasiorek, PhD, MSc Pharm, of Novo Nordisk in Måløv, Denmark. It's the first long-acting compound to target both ...

Weight loss drugs are likely to stay in demand for a long time judging by the obesity trend as shown by latest CDC data ...